Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Me...
April 23 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized
medicine, today announced that its Myriad Women’s Health business
unit will present data from several studies at the 2019 Annual
Clinical and Scientific meeting of The American College of
Obstetricians and Gynecologists (ACOG) being held May 3-6, 2019 in
Nashville, Tenn.
“We are focused on improving the lives of women with our
pioneering science and are looking forward to presenting several
exciting studies at ACOG this year,” said James Goldberg, M.D.,
board certified maternal fetal medicine specialist, medical
geneticist and chief medical officer, Myriad Women’s Health.
“Whether through expanded carrier screening, noninvasive prenatal
screening or hereditary cancer risk assessment, Myriad offers a
wide spectrum of high quality, transformative genetic screening and
testing for women and their families.”
Please visit Myriad Women’s Health at booth #1041 to learn more
about our leading portfolio of women’s health products. Follow
Myriad on Twitter via @myriadgenetics and @MyrWomensHealth and keep
up to date with meeting news and updates by using the hashtag
#ACOG19.
Featured Research at 2019 ACOG |
Product |
Abstract |
Presenting Author |
Presentation Details |
Prequel™
Prenatal Screen |
Clinical Experience for a Noninvasive Prenatal Screen in Assisted
Reproductive Technology Pregnancies |
Susan Hancock |
Poster 34JMay 4, 11:30 a.m.-12:30 p.m. |
Next-Generation Counseling: Technology-Driven Prenatal Screening
Results Disclosure and Management |
Aishwarya Arjunan |
Poster 9JApr 5, 11:30 a.m.-12:30 p.m. |
|
myRisk® Hereditary Cancer |
Opportunity for Cancer Prevention: 1 in 4 Unaffected Women Meet
Hereditary Cancer Testing Criteria |
Leslie Bucheit |
Poster #26OMay 5, 2019 10:00 a.m. – 11:00 a.m. |
Pan-Cancer Panel Testing: Variation in Testing and Results by
Ancestry |
Eva Chalas |
E PosterMay 5, 10:00 a.m.-11:00 a.m. |
|
Foresight® Carrier Screen |
Sequencing-based Carrier Screening for Cystic Fibrosis: Ready for
Prime Time? |
Kyle Beauchamp |
Poster 16O May 5, 10:00 a.m.-11:00 a.m.
|
A Data-Driven Approach for Determining Optimal Content for Expanded
Carrier Screening Panels |
Rotem Ben-Shachar |
Poster #1MMay 4, 3:00 p.m.-4:00 p.m. |
Clinical Utility of Expanded Carrier Screening: Results-Guided
Actionability and Outcomes |
Katie Johansen Taber |
Poster 35JMay 4, 11:30 a.m.-12:30 p.m. |
|
About Myriad myRisk® Hereditary
CancerThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms to evaluate 35 clinically significant genes associated
with eight hereditary cancer sites including: breast, colon,
ovarian, endometrial, pancreatic, prostate and gastric cancers and
melanoma.
About Foresight® Carrier
ScreenThe Myriad Foresight Carrier Screen is designed to
maximize detection of at-risk couples for serious, prevalent, and
clinically-actionable conditions. Foresight has a rigorous disease
selection that focuses on 175+ conditions that provides meaningful
information to patients. Additionally, Foresight offers superior
technology with unmatched detection rates for the vast majority of
genes on the panel (>99% across ethnicities) which means
patients can trust both positive and negative results.
About PrequelTM Prenatal
ScreenThe Myriad Prequel Prenatal Screen is a noninvasive
prenatal screen that uses cell-free DNA (cfDNA) to determine if a
pregnancy is at an increased risk for chromosome abnormalities,
such as Down syndrome. Prequel has been shown to be superior to
screening methods that use maternal age, ultrasound and serum
screening. Additionally, Prequel has a lower false-positive rate
and false-negative rate than these other methods. The Prequel
Prenatal Screen can be ordered with the Foresight Carrier Screen
and offered to all women, including those with high body mass
index, and ovum donor or a twin pregnancy.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on five
strategic imperatives: build upon a solid hereditary cancer
foundation, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate 2020. For
more information on how Myriad is making a difference, please visit
the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the Company’s presentation of new data for
its expanded carrier and noninvasive prenatal screens being
featured at the 2019 American College of Obstetricians and
Gynecologists annual meeting May 3-6, 2019 in Nashville, Tenn.; and
the Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be unable
to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2018, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All
information in this press release is as of the date of the release,
and Myriad undertakes no duty to update this information unless
required by law.
Media Contact: |
Ron Rogers |
|
Investor Contact: |
Scott Gleason |
|
(801) 584-3065 |
|
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024